Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion OVA1(R)+

Vermillion launched its enhanced reflex offering OVA1(R)+ through its wholly owned subsidiary Aspira Labs. OVA1(R)+ combines the technologies behind the company's OVA1(R) and OVERA(R) offerings, which are used to evaluate the risk in women with a pelvic mass prior to surgical treatment of developing ovarian cancer. Patients who undergo OVA1(R)+ and show elevated OVA1(R) results will then have OVERA(R) performed.